Cargando…
HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-trea...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230577/ https://www.ncbi.nlm.nih.gov/pubmed/35746495 http://dx.doi.org/10.3390/vaccines10060887 |
_version_ | 1784735095192551424 |
---|---|
author | Henere, Carla Torné, Aureli Llupià, Anna Aldea, Marta Martí, Cristina Glickman, Ariel Saco, Adela Marimon, Lorena Manzotti, Carolina Rakislova, Natalia Ordi, Jaume del Pino, Marta |
author_facet | Henere, Carla Torné, Aureli Llupià, Anna Aldea, Marta Martí, Cristina Glickman, Ariel Saco, Adela Marimon, Lorena Manzotti, Carolina Rakislova, Natalia Ordi, Jaume del Pino, Marta |
author_sort | Henere, Carla |
collection | PubMed |
description | Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment. |
format | Online Article Text |
id | pubmed-9230577 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92305772022-06-25 HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions Henere, Carla Torné, Aureli Llupià, Anna Aldea, Marta Martí, Cristina Glickman, Ariel Saco, Adela Marimon, Lorena Manzotti, Carolina Rakislova, Natalia Ordi, Jaume del Pino, Marta Vaccines (Basel) Article Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment. MDPI 2022-06-01 /pmc/articles/PMC9230577/ /pubmed/35746495 http://dx.doi.org/10.3390/vaccines10060887 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Henere, Carla Torné, Aureli Llupià, Anna Aldea, Marta Martí, Cristina Glickman, Ariel Saco, Adela Marimon, Lorena Manzotti, Carolina Rakislova, Natalia Ordi, Jaume del Pino, Marta HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title | HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title_full | HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title_fullStr | HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title_full_unstemmed | HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title_short | HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions |
title_sort | hpv vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230577/ https://www.ncbi.nlm.nih.gov/pubmed/35746495 http://dx.doi.org/10.3390/vaccines10060887 |
work_keys_str_mv | AT henerecarla hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT torneaureli hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT llupiaanna hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT aldeamarta hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT marticristina hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT glickmanariel hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT sacoadela hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT marimonlorena hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT manzotticarolina hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT rakislovanatalia hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT ordijaume hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions AT delpinomarta hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions |